Justice Department halts opioid distribution at 2 Tennessee pharmacies

Two pharmacies in Nashville, Tenn., were hit with a restraining order by the U.S. Justice Department that prohibits them from dispensing controlled substance medications, according to the Herald-Citizen.

Advertisement

In a civil complaint unsealed Feb. 8, federal prosecutors claim that Dale Hollow Pharmacy and Xpress Pharmacy of Clay County were dispensing and billing Medicare for prescriptions in violation of the Controlled Substances Act and the False Claims Act. The prescriptions allegedly were filled outside the usual course of professional practice without ensuring they were written for a legitimate medical purpose.

Defendants in the case also include the owner, Thomas Weir, and pharmacists John Polston, Michael Griffith and Larry Larkin.

The unlawful dispensing has been tied to the deaths of at least two people, and several others have been treated for serious overdoses at local hospitals after being dispensed opioids at the pharmacies, according to the complaint

The U.S. is seeking monetary penalties and triple damages.

More articles on opioids:
How Twitter could help combat the opioid crisis
How Atrium Health prevented 23K high-risk opioid prescriptions
Judge orders full release of lawsuit against Purdue Pharma

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.